Aktienanalyse zu Cypherpunk Technologies Inc (CYPH)CYPHCypherpunk Technologies Inc

Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. It operates in the Healthcare sector.

Cypherpunk Technologies Inc (CYPH) is not a good buy right now due to its current price of $2.57, which is significantly above the analyst price target of $0.90. Additionally, the stock has a low RSI of 36.634, indicating it is nearing oversold conditions but still lacks upward momentum. The recent 5-day change of -12.59% and 20-day change of -28.61% suggest a downward trend, and the company's negative earnings per share (EPS) of -0.03 further highlights financial instability. The main risk is the high volatility indicated by an implied volatility of 554.63, which could lead to unpredictable price movements.